C-Bridge Capital Forms AffaMed Therapeutics to Accelerate Commercialization of Biologics in China
February 11, 2019 12:14 ET
|
C-Bridge Capital
SHANGHAI, China, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a new biopharmaceutical company founded and funded by C-Bridge Capital, a healthcare private equity firm focused on the...
優銳醫藥宣佈獲康橋資本領投b輪，用以開展高價值藥物在華商業化
June 28, 2018 17:19 ET
|
C-Bridge Capital
中國上海, June 29, 2018 (GLOBE NEWSWIRE) -- 中國特種藥公司優銳醫藥科技今日宣佈完成總額達2,000萬美元的B輪融資，另獲1,500萬美元資金被指定用於收購新產品，本輪融資由康橋資本領投，這家私募股權機構專注於不斷增長的中國醫療健康市場內的研發與商業化機會，康橋資本董事總經理Neo...
优锐医药宣布获康桥资本领投b轮，用以开展高价值药物在华商业化
June 28, 2018 17:19 ET
|
C-Bridge Capital
中国上海, June 29, 2018 (GLOBE NEWSWIRE) -- 中国特种药公司优锐医药科技今日宣布完成总额达2,000万美元的B轮融资，另获1,500万美元资金被指定用于收购新产品，本轮融资由康桥资本领投，这家私募股权机构专注于不断增长的中国医疗市场内的研发与商业化机会，康桥资本董事总经理Neo...
Nuance Announces series B fundraising led by C-Bridge Capital to commercialize high-value pharmaceuticals in China
June 27, 2018 20:00 ET
|
C-Bridge Capital
SHANGHAI, China, June 27, 2018 (GLOBE NEWSWIRE) -- Nuance Biotech, a China-based specialty pharmaceutical company, today announced Series B fundraising of US$20 million with additional capital US$15...
Everest Medicines子公司获得全球独家授权，开展临床新药FGFR4蛋白激酶抑制剂的研制与商业化
June 26, 2018 19:15 ET
|
C-Bridge Capital
中国上海和美国纽约, June 27, 2018 (GLOBE NEWSWIRE) -- 专注于变革性药物产品的研发和商业化，以应对中国及广大市场上尚未得到满足的关键患者医疗需求的生物制药公司Everest Medicines，今日宣布旗下子公司EverNov已订立全球独家授权协议，开展诺华新药FGFR4（成纤维细胞生长因子受体4号）蛋白激酶抑制剂FGF401的研制和商业化。 ...
Everest Medicines附屬公司獲得全球獨家授權，開展臨床新藥Novel FGFR4蛋白激酶抑制劑的研製與商業化
June 26, 2018 19:15 ET
|
C-Bridge Capital
中國上海和美國紐約, June 27, 2018 (GLOBE NEWSWIRE) -- 生物製藥公司Everest Medicines一直致力從事變更性藥物產品的研發與商業化，以應對中國及廣大市場尚未得到滿足的患者需要，今日宣佈旗下的附屬公司EverNov已訂立全球獨家授權協議，開展Novartis新藥novel...
Everest Medicines Subsidiary Acquires Exclusive Worldwide License to Develop and Commercialize Clinical Stage Novel FGFR4 Kinase Inhibitor
June 25, 2018 20:00 ET
|
C-Bridge Capital
SHANGHAI, China and NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...
Ian Woo加盟Everest Medicines，擔任總裁兼財務總監；並被任命為C-Bridge Capital的董事總經理
June 25, 2018 16:49 ET
|
C-Bridge Capital
上海和紐約, June 26, 2018 (GLOBE NEWSWIRE) -- Everest Medicines今日宣佈，任命Ian Woo擔任總裁兼財務總監；該公司是一家生物製藥公司，專注於開發及銷售變革性藥品，以解決大中華地區患者尚未得到滿足的重大醫療需求。此外，他還被任命為醫療健康私募公司C-Bridge Capital的董事總經理，該公司是Everest...
Ian Woo 加盟 Everest Medicines 公司，担任董事长兼首席财务官；并被任命为 C-Bridge Capital 的常务董事
June 25, 2018 16:49 ET
|
C-Bridge Capital
上海和纽约, June 26, 2018 (GLOBE NEWSWIRE) -- Everest Medicines 公司今日宣布，任命Ian Woo 担任董事长兼首席财务官；该公司是一家生物制药公司，专注于开发和销售变革性药品，以解决大中华地区患者尚未得到满足的重大医疗需求。此外，他还被任命为医疗健康私募公司C-Bridge Capital的常务董事，该公司是Everest...
Ian Woo Joins Everest Medicines as President and Chief Financial Officer; Named Managing Director of C-Bridge Capital
June 24, 2018 20:00 ET
|
C-Bridge Capital
SHANGHAI and NEW YORK, June 24, 2018 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...